NCT06993233

A Study With CIT-013 in HS Patients

A Phase 2a Double Blind, Randomized, Parallel Arm, Placebo-controlled Trial to Investigate the Effects of Two Dose Levels of CIT-013 on Disease Activity in Patients With Hidradenitis Suppurativa

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 96 (estimated)
• Sponsor: Citryll BV · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to learn if CIT-013 works to treat Hidradenitis Suppurativa in adults. It will also learn about the safety of CIT-013. The main questions it aims to answer are: Does CIT-013 lower the disease activity of HS patients? What medical problems do participants have when receiving CIT-013? Researchers will compare CIT-013 to a placebo (a look-alike substance that contains no drug) to see if CIT-013 works to treat the symptoms of HS. Participants will: Take receive 50 or 100 mg CIT-013 or placebo every other week for 12 weeks Visit the clinic once every 2 weeks for checkups and tests Keep monitor their symptoms during this period

Conditions

• Hidradenitis Suppurativa (HS)

Interventions

Type	Name	Description
DRUG	CIT-013 high dose	subcutaneous injection
DRUG	CIT-013 medium dose	subcutaneous injection
DRUG	Placebo	subcutaneous injection

Timeline

• Start date: 2025-10-31
• Primary completion: 2027-04-01
• Completion: 2027-07-01
• First posted: 2025-05-28
• Last updated: 2026-03-25

Locations

24 sites across 6 countries: Canada, Germany, Netherlands, Poland, Spain, United Kingdom